- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00620607
huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
A Phase II, Open Label, Multiple Center Study of huC242-DM4 Given as an Intravenous Infusion Once Every Three Weeks to Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- UAB Comprehensive Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt-Ingram Cancer Center
-
-
Texas
-
Houston, Texas, United States
- U.T. M.D. Anderson Cancer Center
-
San Antonio, Texas, United States
- South Texas Accelerated Research Therapeutics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must understand and voluntarily sign an informed consent.
- Patients must have histological documentation of metastatic or locally advanced (American Joint Committee on Cancer Staging System: Stages IIIA, IIIB, and IV) gastric or gastroesophageal junction adenocarcinoma.
- Patients must have ECOG performance status < 1.
- Patients must be at least 18 years of age.
- Patients who have been treated with only one prior chemotherapy regimen and who have documented disease progression.
- Patients must have confirmation of CanAg expression performed prior to enrollment by immunohistochemical assessment for CanAg on archived biopsy samples.
- Patients must have measurable disease with at least one lesion that can be accurately measured by Response Evaluation Criteria in Solid Tumors (RECIST). The lesion size must be at least 20 mm by conventional radiological techniques or at least 10 mm by spiral CT scan. Disease in an irradiated field as the only site of measurable disease is acceptable if there has been a clear progression of the lesion.
- Patients with reproductive potential must agree to use an effective contraceptive method during the study and for 30 days after receiving the last dose of study drug.
- Women of childbearing potential (WCBP) must have a negative urine or serum pregnancy test within one week prior to enrollment in the study.
- Patients must have any chemotherapy, immunotherapy, hormonal therapy, radiotherapy for cancer or surgery (except for minor surgical procedures) completed at least 3 weeks before starting study medication.
- Patients must have resolution of all clinically significant toxic effects (excluding alopecia) of any prior treatments including surgery, radiotherapy, hormone therapy, immunotherapy, targeted non-cytotoxic therapy, or chemotherapy to grade ≤ 1 by NCI CTCAE v. 3.0 unless otherwise specified in the inclusion laboratory values.
Patients must have adequate organ function including:
Hematopoietic:
i. Absolute neutrophil count > 1,500/mm3. ii. Platelet count > 100,000/mm3. iii. Hemoglobin > 9 g/dL (transfusion allowed).
Renal:
i. Serum creatinine ≤ 1.5 x the upper limit of normal (ULN) ii. Calculated creatinine clearance > 60 mL/min/1.73m2.
Hepatic:
i. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) ≤ 2.5 x ULN ii. Total bilirubin ≤ 1.5 x ULN
Exclusion Criteria:
- Pregnant or lactating women. Women of childbearing potential (WCBP) must have a negative urine or blood test for pregnancy before first treatment.
- Known hypersensitivity to previous monoclonal antibody therapy or maytansinoids.
- Active and uncontrolled infection.
- Known history hepatitis B or C, HIV, or history of alcoholic liver disease.
- Patients with any serious medical or psychiatric disorder that would interfere with patient safety or informed consent.
- Patients with peripheral neuropathy grade 2 or greater.
- Patients with known leptomeningeal disease or progressive brain metastasis. Routine screening with CNS imaging studies (CT or MRI) is required only if clinically indicated.
- Patients with concomitant malignancies or previous malignancies with less than a 2 year disease free interval at the time of dosing. Patients with adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or Stage A low-grade prostate cancer may enroll irrespective of the time of diagnosis.
- Patients who are receiving concomitant chemotherapy, immunotherapy, radiotherapy, or investigational therapy. Radiotherapy for palliation of related bone metastases is permitted upon the agreement between the investigator and the ImmunoGen Medical Monitor and as long as radiation does not involve target lesions that are followed for drug treatment response evaluation.
- Patients with any severe concurrent disease or condition, which in the judgment of the Investigator, would make the patient inappropriate for study participation. The disease or condition include, but are not limited to, one or more of the following: bleeding diathesis, uncontrolled chronic kidney or liver disease, uncontrolled diabetes, history of cardiac disease, myocardial infarction within the past 6 months, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, and uncontrolled hypertension.
- Patients who must use contact lenses and cannot discontinue use of their contact lenses during the course of the clinical study. Patients must discontinue use of contact lenses prior to receiving study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
response rate
Time Frame: year
|
year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
duration of response
Time Frame: as necessary
|
as necessary
|
progression free survival
Time Frame: as necessary
|
as necessary
|
safety and tolerability
Time Frame: while on study
|
while on study
|
Pharmacokinetic (PK) assessment
Time Frame: while on study
|
while on study
|
effect of huC242-DM4 on tumor uptake of FDG
Time Frame: while on study
|
while on study
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMGN 102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stomach Neoplasms
-
Jeeyun LeeRecruitingStomach Cancer, AdenocarcinomaKorea, Republic of
-
Chinese University of Hong KongUnknown
-
Chinese University of Hong KongUnknown
-
National Cancer Center, KoreaUnknownSubmucosal Tumor of StomachKorea, Republic of
-
Xijing Hospital of Digestive DiseasesCompletedStomach Cancer | Esophageal Cancer | Esophageal Dysplasia | Stomach DysplasiaChina
-
Chinese University of Hong KongRecruiting
-
Universitätsklinikum Hamburg-EppendorfOvesco Endoscopy AGSuspendedSubmucosal Tumor of StomachGermany
-
Soonchunhyang University HospitalCompletedMalignant Neoplasm of Stomach | Benign Neoplasm of StomachKorea, Republic of
-
Fujian Cancer HospitalCompletedMalignant Neoplasm of Stomach Stage IVChina
-
Federation Francophone de Cancerologie DigestiveEli Lilly and CompanyActive, not recruitingStomach Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Stomach NeoplasmFrance
Clinical Trials on huC242-DM4
-
ImmunoGen, Inc.CompletedPancreatic Cancer | Non-colorectal CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditionsUnited States
-
BayerTerminatedSolid TumorsUnited States, Italy, France, Poland
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Breast Carcinoma | Triple-Negative Breast CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterImmunoGen, Inc.; Clovis Oncology, Inc.Active, not recruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Folate Receptor Alpha Positive | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Uterine Serous Carcinoma | Recurrent Uterine Carcinosarcoma | Platinum...United States